PTC Therapeutics, Inc.
PTCT· Nasdaq
Released Feb 29, 2024, after the close
10-K filed Feb 29, 2024, 60 days after period end · 0001558370-24-002196
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $307.06M | $167.41M | $165.23M | $118.86M |
| Net Income | -$155.79M | -$170.89M |
PTC Therapeutics, Inc. · CIK 1070081 · Engraved from SEC EDGAR
| -$143.27M |
| -$74.35M |
| EPS Diluted | — | — | — | -$1.08 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.